Drug industry and government officials have set up a task force to address regulatory and other problems facing the pharmaceutical sector following Britain’s decision to leave the European Union.
Drugmakers, which overwhelmingly favored remaining in the EU, account for 25 percent of all UK business research spending and companies have warned that Brexit threatens uncertainty, added complexity and potential drug approval delays.
